×

Biotech and Pharmaceuticals Pharmaceuticals

  • *Teva shares up 16 pct in New York, Lundbeck falls 13 pct. JERUSALEM/ COPENHAGEN, Sept 11- Teva poached Lundbeck's Kare Schultz as its new chief executive on Monday, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future. One key initial decision for Schultz, who will be paid a base salary of $2 million a year...

  • *Teva Pharmaceuticals Industries hires H Lundbeck A/S CEO. JERUSALEM/ COPENHAGEN, Sept 11- Teva poached Lundbeck's Kare Schultz as its new chief executive on Monday, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future. Schultz said he will develop a joint strategy with the board and management...

  • Roche skin cancer drug flunks trial

    John Rountree, partner at Novasecta, comments on the latest news coming out of the pharmaceuticals sector, with comment on Roche and its future in light of its recent trial failure.

  • ZURICH, Sept 11- Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. "In a best case, lampalizumab could have been a significant driver of Roche earnings growth over the next five years," Kepler Cheuvreux analyst David Evans wrote in a note.

  • ZURICH, Sept 11- Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. "In a best case, lampalizumab could have been a significant driver of Roche earnings growth over the next five years," Kepler Cheuvreux analyst David Evans wrote in a note.

  • Sept 11- Teva Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president, the Israel- based drugmaker said on Monday.

  • ZURICH/ MADRID, Sept 11- Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53 percent versus placebo in patients...

  • MADRID, Sept 10- A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. The U.S. drugmaker reported three days ago it was ending the trial well ahead of schedule due to its early success in improving overall survival,...

  • MADRID, Sept 9- AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government's strategy. Soriot said his refusal to sign did not mean the drugmaker disagreed with Britain's decision to leave the...

  • NEW YORK, Sept 8- Former drug company executive Martin Shkreli on Friday asked a judge to throw out part of his criminal conviction, a day after prosecutors sought to have him jailed until his sentencing. District Judge Kiyo Matsumoto to revoke Shkreli's $5 million bail. They said Shkreli could be a "danger to the community," pointing to a Sept. 4 Facebook post in which...

  • Sept 8- Allergan Plc will transfer to the Saint Regis Mohawk Tribe the rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. The tribe, which has sovereign immunity from such challenges, will receive a one-time payment of $13.75 million and annual royalties of around $15...

  • Sept 8- Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. The tribe, which has sovereign immunity from such challenges, will receive a one-time payment of $13.75 million and annual royalties of around $15 million...

  • Allergen reaches agreement regarding Restasis patents

    CNBC's Meg Tirrell reports on shares of Allergan popping on reaching an agreement with eye drug RESTASIS patents.

  • Lead defense attorney Benjamin Brafman walks with former pharmaceutical executive Martin Shkreli after the juror issued a verdict at the U.S. District Court for the Eastern District of New York, August 4, 2017 in the Brooklyn borough of New York City.

    The motion comes a month after a federal court jury in Brooklyn found the "Pharma bro" guilty of three counts related to securities fraud.

  • MADRID, Sept 8- Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair. Research presented at Europe's biggest oncology congress in Madrid adds to evidence that patients with an above average...

  • NEW YORK, Sept 8- U.S. prosecutors on Thursday asked a judge to jail Martin Shkreli while he awaits sentencing for securities fraud, after a Facebook post by the former drug company executive about Hillary Clinton prompted an investigation by the U.S. They pointed to a Sept. 4 Facebook post in which Shkreli offered $5,000 to followers who could grab a strand of...

  • Facebook founder and chief Mark Zuckerberg receives the Axel Springer Award in Berlin on February 25, 2016 Facebook announced it was donating computer servers to a number of research institutions across Europe, starting with Germany, to accelerate research efforts in artificial intelligence (AI) and machine learning.

    Facebook is luring pharmaceutical marketers to its platform and held a breakfast in New York to discuss clinical trials.

  • An employee works in an unit dedicated to the production of insulin pens at the factory of the US pharmaceutical company Eli Lilly in Fegersheim, eastern France.

    Eli Lilly said on Thursday it would lay off about 8 percent of its employees to focus on developing new medicines and cut costs.

  • Eli Lilly CEO: Need to free up resources for new investment

    CNBC's Meg Tirrell reports on comments from the CEO of Eli Lilly following the pharmaceutical giant's announcement of global job cuts.

  • Sept 7- Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees to focus on developing new medicines and cut costs. The drugmaker said the workforce reduction, including those from a U.S. voluntary early retirement program, would amount to yearly savings of about $500 million, beginning in 2018.. Lilly expects charges of about $1.2...